Published in Ann Neurol on January 01, 2005
A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol (2008) 2.44
Lewy bodies. Proc Natl Acad Sci U S A (2006) 2.15
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain (2011) 2.02
Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol (2008) 1.85
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci (2013) 1.82
The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol (2010) 1.80
Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol (2009) 1.73
Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med (2009) 1.72
Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology (2012) 1.69
Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol (2013) 1.52
Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol (2008) 1.46
Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation (2005) 1.41
Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain (2012) 1.40
Update on the pathogenesis of Parkinson's disease. J Neurol (2008) 1.27
Neuropathology of non-Alzheimer degenerative disorders. Int J Clin Exp Pathol (2009) 1.27
Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol (2013) 1.26
Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm (Vienna) (2010) 1.22
Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. Mol Med (2011) 1.16
Differential effects of dopaminergic therapies on dorsal and ventral striatum in Parkinson's disease: implications for cognitive function. Parkinsons Dis (2011) 1.13
The prion hypothesis in Parkinson's disease: Braak to the future. Acta Neuropathol Commun (2013) 1.11
Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts. Acta Neuropathol (2011) 1.06
Association between male gender and cortical Lewy body pathology in large autopsy series. J Neurol (2010) 1.06
Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging (2009) 1.04
Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease. Arch Neurol (2009) 1.03
Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations. Mol Genet Metab (2011) 1.02
Neuronal pentraxin II is highly upregulated in Parkinson's disease and a novel component of Lewy bodies. Acta Neuropathol (2007) 1.00
Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia. Neurobiol Aging (2006) 1.00
Parkinson's disease: a rethink of rodent models. Exp Brain Res (2006) 0.95
Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. Parkinsons Dis (2011) 0.95
Glia and alpha-synuclein in neurodegeneration: A complex interaction. Neurobiol Dis (2015) 0.93
Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease. J Parkinsons Dis (2011) 0.93
Parkinson's disease, cortical dysfunction, and alpha-synuclein. Mov Disord (2011) 0.92
Gait and posture impairment, parkinsonism and cognitive decline in older people. J Neural Transm (Vienna) (2007) 0.91
Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. Acta Neuropathol Commun (2015) 0.90
The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther (2014) 0.88
Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease. Parkinsonism Relat Disord (2009) 0.87
Age and apoE associations with complex pathologic features in Alzheimer's disease. J Neurol Sci (2008) 0.87
Impulsivity and apathy in Parkinson's disease. J Neuropsychol (2013) 0.87
Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis? J Neural Transm (Vienna) (2007) 0.87
Alpha-synuclein aggregation induced by brief ischemia negatively impacts neuronal survival in vivo: a study in [A30P]alpha-synuclein transgenic mouse. J Cereb Blood Flow Metab (2010) 0.83
Parkinson's disease dementia: a diminished role for the Lewy body. Parkinsonism Relat Disord (2009) 0.83
Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease. FEBS Lett (2015) 0.78
Alpha-synucleinopathy and neuropsychological symptoms in a population-based cohort of the elderly. Alzheimers Res Ther (2015) 0.76
Hippocampal α-Synuclein in Dementia with Lewy Bodies Contributes to Memory Impairment and Is Consistent with Spread of Pathology. J Neurosci (2016) 0.75
Alpha-synuclein aggregation and its relation to neurodegenerative diseases. Ann Neurol (2005) 0.75
Oculo-Visual Dysfunction in Parkinson's Disease. J Parkinsons Dis (2015) 0.75
Seeding and transgenic overexpression of alpha-synuclein triggers dendritic spine pathology in the neocortex. EMBO Mol Med (2017) 0.75
Exploring Braak's Hypothesis of Parkinson's Disease. Front Neurol (2017) 0.75
Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms. Front Neurol (2017) 0.75
Neuropathology of Parkinson disease. Parkinsonism Relat Disord (2017) 0.75
Embryonic development of selectively vulnerable neurons in Parkinson's disease. NPJ Parkinsons Dis (2017) 0.75
Parkinson's disease: Microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegeneration. Surg Neurol Int (2017) 0.75
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (2006) 8.15
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 3.95
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol (2009) 3.34
The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci U S A (2008) 2.30
Association between blood pressure and survival over 9 years in a general population aged 85 and older. J Am Geriatr Soc (2006) 2.21
Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol (2008) 2.19
CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol Aging (2006) 1.96
Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am J Hum Genet (2010) 1.89
Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. Ann Neurol (2010) 1.74
Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol (2003) 1.64
Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions visualized with ubiquitin-binding protein p62 immunohistochemistry. J Neuropathol Exp Neurol (2008) 1.55
Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J (2005) 1.54
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol (2008) 1.51
Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol (2008) 1.46
CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology (2005) 1.46
Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol (2003) 1.41
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol (2002) 1.41
An antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology. Acta Neuropathol (2012) 1.33
The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium. Am J Epidemiol (2015) 1.27
Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol (2003) 1.18
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol (2015) 1.17
Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord (2008) 1.17
Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFβ2 in vascular abnormalization. J Pathol (2012) 1.16
Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients. Neurobiol Aging (2007) 1.15
Ubiquitinated p62-positive, TDP-43-negative inclusions in cerebellum in frontotemporal lobar degeneration with TAR DNA binding protein 43. Neuropathology (2009) 1.14
Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol (2005) 1.14
Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol (2002) 1.14
Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer's disease. Int J Geriatr Psychiatry (2010) 1.13
TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol (2014) 1.08
Long-term epilepsy surgery outcomes in patients with MRI-negative temporal lobe epilepsy. Epilepsia (2010) 1.07
CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy. J Alzheimers Dis (2008) 1.06
Postmortem examination of vascular lesions in cognitive impairment: a survey among neuropathological services. Stroke (2006) 1.05
A multi-metabolite analysis of serum by 1H NMR spectroscopy: early systemic signs of Alzheimer's disease. Biochem Biophys Res Commun (2008) 1.04
Pro-inflammatory interleukin-18 increases Alzheimer's disease-associated amyloid-β production in human neuron-like cells. J Neuroinflammation (2012) 1.03
Emerging role of p62/sequestosome-1 in the pathogenesis of Alzheimer's disease. Prog Neurobiol (2011) 1.02
Atrial fibrillation, stroke, and cognition: a longitudinal population-based study of people aged 85 and older. Stroke (2007) 1.02
Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain. Neurobiol Dis (2005) 1.01
Fine mapping of a multiple sclerosis locus to 2.5 Mb on chromosome 17q22-q24. Hum Mol Genet (2002) 1.01
Immunohistochemical visualization of amyloid-beta protein precursor and amyloid-beta in extra- and intracellular compartments in the human brain. J Alzheimers Dis (2010) 1.00
Cortical brain biopsy in long-term prognostication of 468 patients with possible normal pressure hydrocephalus. Neurodegener Dis (2012) 0.99
Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain. Neurobiol Aging (2005) 0.99
Prenatal diagnosis of placenta accreta and percreta with ultrasonography, color Doppler, and magnetic resonance imaging. Obstet Gynecol (2004) 0.98
Assessments of the accumulation severities of amyloid beta-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brains. Neurobiol Dis (2006) 0.97
Neurofilament ELISA validation. J Immunol Methods (2009) 0.96
Use of a genetic isolate to identify rare disease variants: C7 on 5p associated with MS. Hum Mol Genet (2009) 0.96
Beta-amyloid aggregation in human brains with cerebrovascular lesions. Stroke (2006) 0.95
Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Am J Psychiatry (2003) 0.95
Proteomic analysis of protein oxidation in Alzheimer's disease brain. Electrophoresis (2002) 0.95
Glycosylation changes in Alzheimer's disease as revealed by a proteomic approach. Neurosci Lett (2004) 0.94
Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject. Neuropathology (2005) 0.94
The effect of prolonged fixation time on immunohistochemical staining of common neurodegenerative disease markers. J Neuropathol Exp Neurol (2010) 0.94
Both N-methyl-D-aspartate (NMDA) and non-NMDA receptors mediate glutamate-induced cleavage of the cyclin-dependent kinase 5 (cdk5) activator p35 in cultured rat hippocampal neurons. Neurosci Lett (2004) 0.94
Consensus recommendations on pathologic changes in the hippocampus: a postmortem multicenter inter-rater study. J Neuropathol Exp Neurol (2013) 0.93
Vascular risk factors and dementia in the general population aged >85 years: prospective population-based study. Neurobiol Aging (2008) 0.93
Cystatin C expression is associated with granule cell dispersion in epilepsy. Ann Neurol (2005) 0.92
Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet Genomics (2008) 0.91
Hyperphosphorylated tau in young and middle-aged subjects. Acta Neuropathol (2011) 0.91
No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2007) 0.91
TAR-DNA binding protein-43 and alterations in the hippocampus. J Neural Transm (Vienna) (2011) 0.91
Cardiovascular diseases and hippocampal infarcts. Hippocampus (2011) 0.90
An update on clinical proteomics in Alzheimer's research. J Neurochem (2009) 0.90
Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease. Clin Chem (2007) 0.90
A follow-up study of chromosome 19q13 in multiple sclerosis susceptibility. J Neuroimmunol (2009) 0.90
Perfusion and diffusion MRI combined with ¹¹C-methionine PET in the preoperative evaluation of suspected adult low-grade gliomas. J Neurooncol (2013) 0.88
CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid. Neurosci Lett (2009) 0.88
A study of embryonic stem cell-related proteins in human astrocytomas: identification of Nanog as a predictor of survival. Int J Cancer (2013) 0.88
Poor cognitive outcome in shunt-responsive idiopathic normal pressure hydrocephalus. Neurosurgery (2013) 0.87
Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. Neuroreport (2004) 0.87
Human postmortem brain tissue and 2-mm tissue microarrays. Appl Immunohistochem Mol Morphol (2006) 0.87
Interleukin-18 increases expression of kinases involved in tau phosphorylation in SH-SY5Y neuroblastoma cells. J Neuroimmunol (2008) 0.87
Mast cell accumulation in glioblastoma with a potential role for stem cell factor and chemokine CXCL12. PLoS One (2011) 0.86
[Update on current care guidelines. The diagnosis and medical treatment of memory disorders]. Duodecim (2010) 0.86
Integration of expression profiles and genetic mapping data to identify candidate genes in intracranial aneurysm. Physiol Genomics (2007) 0.86
Distribution of collagen XVII in the human brain. Brain Res (2007) 0.86
Collagen XVII is expressed in human CNS neurons. Matrix Biol (2006) 0.85
Potential cost-effectiveness of a family-based program in mild Alzheimer's disease patients. Eur J Health Econ (2004) 0.85
GRN variant rs5848 reduces plasma and brain levels of granulin in Alzheimer's disease patients. J Alzheimers Dis (2013) 0.85
Subtyping of gliomas of various WHO grades by the application of immunohistochemistry. Histopathology (2013) 0.84
Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J Clin Endocrinol Metab (2013) 0.84
Analysis of human tau in cerebrospinal fluid. J Proteome Res (2010) 0.84
Heavy alcohol consumption and neuropathological lesions: a post-mortem human study. J Neurosci Res (2009) 0.84
Influence of phosphorylation of p35, an activator of cyclin-dependent kinase 5 (cdk5), on the proteolysis of p35. Brain Res Mol Brain Res (2002) 0.83